Biovica ended the fiscal year with strong growth in both the fourth quarter and for the full fiscal year, while making important progress in expanding the clinical evidence base, the Pharma Services area, and adoption of DiviTum TKa in the USA. Biovica is embarking on the next commercial phase with a sharper focus, higher efficiency, and greater financial discipline.

Q4 (Feb 2026 – April 2026) (comparison figures are for the same period 2024/2025)

• Net sales amounted to SEK 4,815 (2,332), corresponding to an increase of 107%.
  In local currency, net sales increased by 129%.
• Cash flow from operating activities amounted to SEK -15,984 (- 17,826) thousand.
• At the end of the quarter, cash and cash equivalents amounted to SEK 70,412 (24,415) thousand.

Fiscal year 25/26 (May 2025– April 2026) (comparison figures are for the same period 24/25)

• Net sales amounted to SEK 13,380 (8,619), corresponding to an increase of 55%.
  In local currency, net sales increased by 74%.
• Cash flow from operating activities during the period amounted to SEK -62,807 ( -85,367) thousand.

Webcast:
When: 17 June 2026, 3 PM to 4 PM CET
Where: https://www.redeye.se/events/1170839/live-q-biovica
How: Broadcast in English

CEO’s comments

During the fourth quarter of fiscal year 2025/26, Biovica further strengthened its position in the IVD market and Pharma Services in the U.S. I assumed the role of CEO on 1 May 2026, just as the company enters the next important phase of its commercial growth. After my first month as CEO, my assessment of the company is clear: Biovica has a strong scientific foundation, a differentiated product and considerable potential.

My mandate is thus to make Biovica more focused, more efficient and more commercially impactful. Through a sharper allocation of resources toward the most value-creating opportunities, we can improve cash flow, enhance resilience, and accelerate progress toward our strategic ambitions.

Our path forward is clear. We will continue to expand the body of clinical evidence, accelerate commercial adoption, and deepen our collaboration with leading clinics, healthcare providers, payers, and pharmaceutical companies. At the same time, we must sharpen our priorities and allocate resources to the areas with the greatest value-creation potential, creating a more efficient organization with improved cash flow. These important initiatives will strengthen Biovica’s financial resilience and create better conditions for realizing the commercial potential.

Growing body of evidence
Further progress was made during the quarter in expanding the body of clinical evidence. New data presented during the period confirmed the strong prognostic correlations for DiviTum TKa in metastatic breast cancer, reinforcing the test’s clinical utility as a decision-support tool in treatment selection. Additionally, new data presented at the American Association for Cancer Research (AACR) Annual Meeting expanded the clinical evidence supporting the use TKa in immune checkpoint inhibitor therapy and CDK inhibitor dose optimization.
Subsequent to the end of the fiscal year, new data was presented at ESMO Breast Cancer 2026 highlighting the utility of TKa across a variety of treatment settings, reinforcing its relevance as a dynamic biomarker for treatment monitoring and drug development. It aligns well with the growing demand for biomarkers that support more personalized oncology treatment.

Sharper commercial focus
Demand in Pharma Services remains strong, driven by the need for validated pharmacodynamic (PD) biomarkers in clinical development and heightened regulatory focus on dose optimization. Our collaborations with leading pharmaceutical companies continue to advance through recurring and expanded assignments, underscoring the importance of this business area as a key growth driver for Biovica.

We are also seeing growing commercial momentum in the U.S., where adoption of DiviTum TKa continues to increase steadily. This confirms that prior investments in establishing a market presence are now translating into concrete clinical use. Going forward, we will continue to build on this foundation through a more disciplined commercial model, clearer customer prioritization, and better alignment across clinical evidence generation, payer engagement, and go-to-market activities.

More focused strategy and improved cash flow
My first priority going forward is to ensure that Biovica is properly structured for the next phase of growth, with the right organization, cost base, and commercial focus. We must therefore prioritize the markets, customer segments, and partnerships that offer the greatest potential for product adoption, revenue growth, and long-term strategic value.
The objective is not merely to reduce costs, but to create a more focused, efficient and sustainable organization. By improving financial discipline, sharpening priorities, and allocating resources more effectively, we can better capitalize on the investments already made in clinical evidence, regulatory acceptance, and commercial infrastructure.

Well positioned for the next phase
We enter the new fiscal year with strong momentum and a clear set of priorities: to accelerate adoption of DiviTum TKa, broaden its use, deepen our strategic partnerships, and ensure that Biovica operates more efficiently and with greater financial discipline. The growing body of evidence, our established presence in the USA, and a stronger position in Pharma Services provide a solid foundation for the next phase of the company’s growth.

I would like to sincerely thank Biovica’s employees for their commitment and work during this important period for the company. The talent, expertise, and drive within the organization are important assets as we move into this next phase.

My priority as CEO is clear – to realize Biovica’s commercial potential through streamlining initiatives and a more scalable business model. Doing so will better position the company to achieve its strategic ambitions and deliver long-term value to patients, healthcare providers, and shareholders.

Theis Kipling, CEO

Significant events during the fourth quarter

• Data confirm strong prognostic correlations for DiviTum TKa in metastatic breast cancer.
• Biovica’s CEO, Anders Rylander, announced that he will step down as CEO during 2026 as part of a structured succession process.
• New AACR data expand evidence for TKa in immunotherapy-treated patients and CDK inhibitor dose optimization.
• The Board of Directors has appointed Theis Kipling as the new CEO, effective 1 May 2026.

Significant events after the end of the quarter

• New ESMO data highlights TKa across multiple treatment settings.
• CFO Anders Morén has resigned on his own initiative. He will remain in his current role during the six-month notice period.
• Biovica received an expanded work order from a clinical-stage oncology company developing a next-generation CDK inhibitor.
• New Phase III data shows that DiviTum TKa captures treatment-specific biological response for metastatic breast cancer.
• Biovica initiates termination of Distribution contracts within EU to focus resources on US and Pharma Services.